SCHEMBL214329

SCHEMBL214329

Cc1ccc(Cl)cc1NC(=O)c1nc[nH]c1C(=O)Nc1nc2ccc(OC3CCN(C(=O)O)CC3)cc2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.41
MAPT P10636 4/20 0.39
KDM4E B2RXH2 2/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
BRD4 O60885 1/20 0.36
CNR2 P34972 1/20 0.36
GAA P10253 2/20 0.35
MEN1 O00255 1/20 0.35
RPS6KA2 Q15349 1/20 0.35
LPAR2 Q9HBW0 1/20 0.35
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4110599 0.93 HRH4 (0.42) HRH4MAPTKDM4EKMT2AALDH1A1
SCHEMBL214626 0.91 KDM4E (0.39) MAPTKDM4EKMT2AALDH1A1SMN1; SMN2
SCHEMBL214456 0.91 CHEK2 (0.44) HRH4MAPTKMT2AALDH1A1MEN1
SCHEMBL10268072 0.85 ALDH1A1 (0.39) MAPTKDM4EKMT2AALDH1A1SMN1; SMN2
SCHEMBL214816 0.85 KMT2A (0.44) MAPTKDM4EKMT2AALDH1A1SMN1; SMN2
SCHEMBL14222300 0.85 KMT2A (0.44) MAPTKDM4EKMT2AALDH1A1SMN1; SMN2
SCHEMBL213560 0.84 CHEK2 (0.44) HRH4MAPTKMT2AALDH1A1MEN1
SCHEMBL216261 0.84 ALDH1A1 (0.41) MAPTKDM4EKMT2AALDH1A1SMN1; SMN2
SCHEMBL14222391 0.84 HRH4 (0.44) HRH4MAPTKDM4EKMT2AALDH1A1
SCHEMBL10267512 0.84 CHEK2 (0.39) HRH4MAPTKDM4EKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 HRH4 1909/4885MAPT 2138/4885KDM4E 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.